Silvia Beghi
Overview
Explore the profile of Silvia Beghi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostopoulos N, Costabile F, Krimitza E, Beghi S, Goia D, Perales-Linares R, et al.
Blood Adv
. 2024 Aug;
8(24):6308-6320.
PMID: 39213422
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CART-19) represents a significant advance in the treatment of patients with relapsed or refractory CD19+ B-cell lymphomas. However, a significant portion of...
2.
Perales-Linares R, Leli N, Mohei H, Beghi S, Rivera O, Kostopoulos N, et al.
Cancer Res
. 2023 Aug;
83(21):3562-3576.
PMID: 37578274
Significance: Parkin prevents immune evasion by regulating tumor antigen processing and presentation through the PTEN/Akt network, which has important implications for immunotherapy treatments in patients with Parkin-deficient tumors.
3.
Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, et al.
Mol Ther
. 2023 Jan;
31(3):686-700.
PMID: 36641624
Several studies have shown the influence of commensal microbes on T cell function, specifically in the setting of checkpoint immunotherapy for cancer. In this study, we investigated how vancomycin-induced gut...
4.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Oct;
29(11):2954.
PMID: 36253610
No abstract available.
5.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Mar;
28(4):713-723.
PMID: 35288695
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and...
6.
Pierini S, Mishra A, Perales-Linares R, Uribe-Herranz M, Beghi S, Giglio A, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33563772
Background: Tumor endothelial marker 1 (TEM1) is a protein expressed in the tumor-associated endothelium and/or stroma of various types of cancer. We previously demonstrated that immunization with a plasmid-DNA vaccine...
7.
Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gomez L, Verginadis I, Bittinger K, et al.
J Clin Invest
. 2019 Dec;
130(1):466-479.
PMID: 31815742
Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA)...
8.
Pustylnikov S, Costabile F, Beghi S, Facciabene A
Transl Res
. 2018 Aug;
202:35-51.
PMID: 30144423
An essential advantage during eukaryotic cell evolution was the acquisition of a network of mitochondria as a source of energy for cell metabolism and contrary to conventional wisdom, functional mitochondria...